Sign In
Buy PRTG
$6.81
+0 (+0%)
At Close: Dec 02, 2025
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
12:37pm, Wednesday, 03'rd Sep 2025
AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointe
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
09:00am, Wednesday, 03'rd Sep 2025
DOVER, DE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
04:15pm, Friday, 25'th Jul 2025
DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British V
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
07:00am, Wednesday, 25'th Jun 2025
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British V
Portage Biotech and Compedica Stock-for-Stock Exchange
06:00am, Monday, 09'th Jun 2025
DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announc
Portage Biotech Stock Surges As It Prepares For Human Trial
10:37am, Monday, 28'th Apr 2025
Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human tria
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
06:00am, Monday, 28'th Apr 2025
DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a
Why Is Portage Biotech Stock Skyrocketing Friday?
01:13pm, Friday, 28'th Mar 2025
Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial
06:02pm, Thursday, 27'th Mar 2025
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
08:00am, Wednesday, 12'th Mar 2025
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients Encouraging Safety Profile Supports Progression Toward First Dual-Admi
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
04:15pm, Wednesday, 12'th Feb 2025
DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therap
Portage Biotech Announces Completion of $2.15 Million Private Financing
04:30pm, Thursday, 30'th Jan 2025
DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therap
WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative th
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
04:15pm, Thursday, 12'th Dec 2024
No impact at this time on the listing of the Company's Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotec
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
04:05pm, Tuesday, 26'th Nov 2024
WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-ta
